| Identification | Back Directory | [Name]
rosoxacin | [CAS]
40034-42-2 | [Synonyms]
PD-107522
Win-35213
rosoxacin
Acrosoxacin
rosoxacin USP/EP/BP
1-Ethyl-4-oxo-7-(4-pyridyl)-1,4-dihydroquinoline-3-carboxylic Acid
1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid
1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid
3-Quinolinecarboxylicacid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- | [EINECS(EC#)]
254-758-4 | [Molecular Formula]
C17H14N2O3 | [MDL Number]
MFCD00057294 | [MOL File]
40034-42-2.mol | [Molecular Weight]
294.3 |
| Hazard Information | Back Directory | [Uses]
Antibacterial. | [Definition]
ChEBI: A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by an ethyl group at position 1 and by a pyridin-4-yl group at position 7. An antibacterial drug, active against Neisseria gonorrhoeae, it has be
n used for treating urinary tract infections and certain sexually transmitted diseases. | [Brand name]
Roxadyl (Sterling Winthrop). | [Pharmacokinetics]
A single oral dose of 300 mg produces a mean peak plasma concentration of 4–5 mg/L at about 2–4 h, with an apparent elimination half-life of about 6 h. Elimination in the urine is partly as the N-oxide metabolite and the glucuronide of this metabolite.
Side effects are those common to quinolones, notably gastrointestinal tract and CNS disturbances. About 50% of patients treated with single oral doses of 100–400 mg developed dizziness, drowsiness, altered visual perception and other CNS effects.
It is effective as single-dose treatment of patients with urethral and anorectal gonorrhea, but coexistent C. trachomatis infection is not eliminated from most patients and postgonococcal urethritis develops in up to 30%. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
DebyeTec.com Inc.
|
| Tel: |
18086626237 18086626237 |
| Website: |
https://www.debyetec.com |
|